Spots Global Cancer Trial Database for esophagogastric junction cancer
Every month we try and update this database with for esophagogastric junction cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2) | NCT04752358 | Esophageal Canc... Esophagogastric... | Autologous gene... | 18 Years - 75 Years | Adaptimmune | |
| A Randomized, Double Blind Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma After Prior Chemotherapy | NCT01248403 | Advanced Gastri... Esophagogastric... | Paclitaxel RAD001 | 18 Years - | Krankenhaus Nordwest | |
| Phase II/III Study Comparing Chemoradiotherapy With Radiotherapy in Elderly Patients With Esophageal or Esophagogastric Cancer - 3JECROG P-01 | NCT02979691 | Esophagus Cance... Esophagogastric... Radiotherapy; C... Chemoradiation | SIB-IMRT S-1 | 70 Years - | ChineseAMS | |
| Development of a Clinical Decision Support System With Artificial Intelligence for Cancer Care | NCT04675138 | Gastric Cancer Esophageal Canc... Esophagogastric... | No intervention... | 21 Years - | National University Hospital, Singapore | |
| MRI and CT Simulation in the Evaluation of Tumor Response and Target Volume Definition for Esophageal or Esophagogastric Cancer Patients Undergoing Chemoradiotherapy | NCT02988921 | Esophagus Cance... Esophagogastric... | MRI and CT Ratiotherapy Paclitaxel, pla... | 18 Years - | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| Chemotherapy for Potentially Resectable Locally Advanced Esophagogastric Junction Carcinoma | NCT03211377 | Esophagogastric... | 18 Years - | Anyang Tumor Hospital | ||
| Neoadjuvant Cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial | NCT06310473 | Gastric Cancer Esophagogastric... | Cadonilimab Oxaliplatin Capecitabine | 18 Years - 75 Years | Nanfang Hospital, Southern Medical University | |
| MRI and CT Simulation in the Evaluation of Tumor Response and Target Volume Definition for Esophageal or Esophagogastric Cancer Patients Undergoing Chemoradiotherapy | NCT02988921 | Esophagus Cance... Esophagogastric... | MRI and CT Ratiotherapy Paclitaxel, pla... | 18 Years - | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors | NCT04400383 | Solid Tumor Gastric Cancer Pancreatic Aden... | AB011 Injection | 18 Years - 80 Years | CARsgen Therapeutics Co., Ltd. | |
| A Randomized, Double Blind Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma After Prior Chemotherapy | NCT01248403 | Advanced Gastri... Esophagogastric... | Paclitaxel RAD001 | 18 Years - | Krankenhaus Nordwest | |
| Neoadjuvant Immunotherapy and Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial | NCT04744649 | Gastric Cancer Stomach Neoplas... | XELOX or SOX JS001+XELOX or ... | 18 Years - 75 Years | Nanfang Hospital, Southern Medical University | |
| Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer | NCT04821778 | Esophagus Cance... Esophagogastric... Chemoradiation Targeted Therap... Immunotherapy Chemotherapy Ef... | Radiotherapy Platinum based ... Paclitaxel base... Immunotherapy 5-FU Analog bas... Nimotuzumab | 18 Years - | ChineseAMS | |
| Clinical Trial to Evaluate the Safety and Efficacy of IM92 CAR-T Cells Therapy in Patients With Advanced Gastric or Pancreatic Adenocarcinoma | NCT05275062 | Advanced Solid ... Gastric Cancer Esophagogastric... Pancreatic Canc... | IM92 CAR-T cell... | 18 Years - 75 Years | Beijing Immunochina Medical Science & Technology Co., Ltd. | |
| Development of a Clinical Decision Support System With Artificial Intelligence for Cancer Care | NCT04675138 | Gastric Cancer Esophageal Canc... Esophagogastric... | No intervention... | 21 Years - | National University Hospital, Singapore | |
| Clinical Trial to Evaluate the Safety and Efficacy of IM92 CAR-T Cells Therapy in Patients With Advanced Gastric or Pancreatic Adenocarcinoma | NCT05275062 | Advanced Solid ... Gastric Cancer Esophagogastric... Pancreatic Canc... | IM92 CAR-T cell... | 18 Years - 75 Years | Beijing Immunochina Medical Science & Technology Co., Ltd. | |
| ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer | NCT05245760 | Esophageal Canc... Esophagogastric... | Intravenous Tis... Chemotherapy Fractionated ra... Esophagectomy | 18 Years - 80 Years | University of Kentucky | |
| Neoadjuvant Immunotherapy and Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial | NCT04744649 | Gastric Cancer Stomach Neoplas... | XELOX or SOX JS001+XELOX or ... | 18 Years - 75 Years | Nanfang Hospital, Southern Medical University | |
| Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection | NCT04581473 | Gastric Adenoca... Pancreatic Canc... Gastroesophagea... | CT041 autologou... Physician's Cho... | 18 Years - 75 Years | CARsgen Therapeutics Co., Ltd. | |
| Development of a Clinical Decision Support System With Artificial Intelligence for Cancer Care | NCT04675138 | Gastric Cancer Esophageal Canc... Esophagogastric... | No intervention... | 21 Years - | National University Hospital, Singapore | |
| ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2) | NCT04752358 | Esophageal Canc... Esophagogastric... | Autologous gene... | 18 Years - 75 Years | Adaptimmune | |
| Efficacy of Cetuximab in Combination With Irinotecan and 5- FU/FA in Treatment of Metastatic Gastric Cancer | NCT01123811 | Adenocarcinoma ... | Cetuximab IF | 18 Years - 75 Years | Johannes Gutenberg University Mainz |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
